Effects of co-administration of
Qurs Tabasheer Sartani
Unani formulations
ATT drugs
adverse drug reaction; A
rq Hara Bhara
liver function
toxicity
tuberculosis
Journal
Journal of complementary & integrative medicine
ISSN: 1553-3840
Titre abrégé: J Complement Integr Med
Pays: Germany
ID NLM: 101313855
Informations de publication
Date de publication:
10 May 2021
10 May 2021
Historique:
received:
23
07
2020
accepted:
17
09
2020
pubmed:
9
5
2021
medline:
29
10
2021
entrez:
8
5
2021
Statut:
epublish
Résumé
Tuberculosis continues to be a major public health problem globally, despite incredible advancements in healthcare system. In QTS and AHB were prepared individually and mixed to achieve final compound The administration of UPF, CAT-I and UPF + CAT-I altered the levels of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase (GGT) and haematological markers. These alterations were within permissible range and randomly distributed among groups during various time points. Administration of CAT-I alone resulted in moderate histopathological changes which were completely abrogated in CAT-I + UPF co-administered animals. The co-administration of UPF with CAT-I improved the plasma peak rifampicin (RIF) levels, without altering the liver and kidney functions. The co-administration of UPF with ATT improved liver and kidney functions and increased the plasma levels of RIF. These beneficial findings provide a scope to evaluate the pharmacokinetic studies in humans.
Identifiants
pubmed: 33964191
pii: jcim-2020-0262
doi: 10.1515/jcim-2020-0262
doi:
Substances chimiques
Antitubercular Agents
0
gamma-Glutamyltransferase
EC 2.3.2.2
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-525Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
World Health Organization. Global tuberculosis report 2017. Available at: https://www.who.int/tb/publications/global_report/gtbr2017_main_text.pdf?ua=1.
Harries, AD, Kumar, AMV, Satyanarayana, S, Lin, Y, Zachariah, R, Lonnroth, K, et al.. Addressing diabetes mellitus as part of the strategy for ending TB. Trans R Soc Trop Med Hyg 2016;110:173–9. https://doi.org/10.1093/trstmh/trv111.
Agal, S, Baijal, R, Pramanik, S, Patel, N, Gupte, P, Kamani, P, et al.. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005;20:1745–52. https://doi.org/10.1111/j.1440-1746.2005.04048.x.
Awofeso, N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ 2008;86:B–D. https://doi.org/10.2471/blt.07.043802.
Yee, D, Valiquette, C, Pelletier, M, Parisien, I, Rocher, I, Menzies, D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472–7. https://doi.org/10.1164/rccm.200206-626oc.
Mujahid, M, Hussain, T, Siddiqui, HH, Hussain, A. Evaluation of hepatoprotective potential of erythrinaindica leaves against antitubercular drugs induced hepatotoxicity in experimental rats. J Ayurveda Integr Med 2017;8:7–12. https://doi.org/10.1016/j.jaim.2016.10.005.
Jaswal, A, Sharma, M, Raghuvanshi, S, Sharma, S, Reshi, MS, Uthra, C, et al.. Therapeutic efficacy of Nigella sativa linn. Against antituberculosis drug induced hepatic injury in wistar rats. J Environ Pathol Toxicol Oncol 2016;35:59–71. https://doi.org/10.1615/jenvironpatholtoxicoloncol.2016013789.
Pal, R, Vaiphei, K, Sikander, A, Singh, K, Rana, SV. Effect of garlic on isoniazid and rifampicin-induced hepatic injury in rats. World J Gastroenterol 2006;12:636–9. https://doi.org/10.3748/wjg.v12.i4.636.
Eminzade, S, Uras, F, Izzettin, FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond) 2008;5:18. https://doi.org/10.1186/1743-7075-5-18.
Sherwani, AM, Mohammad Zulkifle, R. A pilot trial of jawarishamla as adjuvant to anti-tubercular treatment drugs for control of adverse reactions in dots regime in pulmonary TB. J IMA 2013;44:1–9. https://doi.org/10.5915/44-1-9988.
Kabiruddin, M. Bayaz-e-kabir. Lahore: HamdardKutubKhanaurdu Bazar, Matbatul Arabiya; 1921:110–2 pp.
Khan, A. Ramooz-e-Azam. New Delhi: Central Council for Research in Unani Medicine; 2006:319–24 pp.
Khan, A. Qarabadeen-e-Azam. New Delhi: Aijaz Publishing House; 1996:510–6 pp.
Arzani, MA. Qarabadeen-e-Qadri. New Delhi: Central Council for Research in Unani Medicine; 2009:442–3 pp.
Shin, JW, Seol, IC, Son, CG. Interpretation of animal dose and human equivalent dose for drug development. J Korean Med 2010;31:1–7.
Kumar, AK, Sudha, V, Ramachandran, G. Simple and rapid liquid chromatography method for simultaneous determination of isoniazid and pyrazinamide in plasma. SAARC J Tuberc Lung Dis HIV/AIDS 2012;9:13–8.
Kumar, AK, Chandra, I, Geetha, R, Chelvi, KS, Lalitha, V, Prema, G. A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine. Indian J Pharmacol 2004;36:231–3.
Singh, S, Kumar, S. Tuberculosis in India: road to elimination. Int J Prev Med 2019;10:114. https://doi.org/10.4103/ijpvm.ijpvm_492_17.
Schaberg, T, Rebhan, K, Lode, H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026–30. https://doi.org/10.1183/09031936.96.09102026.
Ostapowicz, G, Fontana, RJ, Schiodt, FV, Larson, A, Davern, TJ, Han, HB, et al.. Results of a prospective study of acute liver failure at 17 Tertiary Care Centers in the United States. Ann Int Med 2002;137:947–54. https://doi.org/10.7326/0003-4819-137-12-200212170-00007.
Ramappa, V, Aithal, GP. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol 2013;3:37–49. https://doi.org/10.1016/j.jceh.2012.12.001.
Baniasadi, S, Eftekhari, P, Tabarsi, P, Fahimi, F, Raoufy, MR, Masjedi, MR, et al.. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010;22:1235–38. https://doi.org/10.1097/meg.0b013e32833aa11b.
Hasanain, AF, Zayed, AH, Mahdy, RE, Nafee, AM. Cholecalciferol for prophylaxis against antituberculosis therapy-induced liver disorders among naive patients with pulmonary tuberculosis: a randomized, comparative study. Int J Mycobacteriol 2017;6:149–55. https://doi.org/10.4103/ijmy.ijmy_19_17.
Adhvaryu, MR, Reddy, N, Vakharia, BC. Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World J Gastroenterol 2008;14:4753–62. https://doi.org/10.3748/wjg.14.4753.
Ormerod, LP, Horsfield, N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996;77:37–42. https://doi.org/10.1016/s0962-8479(96)90073-8.
Ravishah, S, Manjula, SN, Mruthunjaya, K, Krishnanand, P, Pramod, CK, Madhu, RM, et al.. Hepatoprotective activity of roots of Lawsonia inermis against paracetamol and antitubercular drugs induced hepatotoxicity in rats. Int J Pharm 2012;2:306–16.
Kassa, E, Enawgaw, B, Gelaw, A, Gelaw, B. Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at university of Gondar Hospital, Northwest Ethiopia. BMC Hematol 2016;16:1–11. https://doi.org/10.1186/s12878-015-0037-1.
Yue, J, Peng, R, Yang, J, Kong, R, Liu, J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 2004;25:699–704.
Acocella, G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 1983;5:S428–32. https://doi.org/10.1093/clinids/5.supplement_3.s428.
Burk, O, Koch, I, Raucy, J, Hustert, E, Eichelbaum, M, Brockmoller, J, et al.. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004;279:38379–85. https://doi.org/10.1074/jbc.m404949200.
Sarma, GR, Immanuel, C, Kailasam, S, Narayana, AS, Venkatesan, P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986;133:1072–5. https://doi.org/10.1164/arrd.1986.133.6.1072.